Castle Biosciences/$CSTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Ticker
$CSTL
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
784
ISIN
US14843C1053
Website
CSTL Metrics
BasicAdvanced
$573M
-
-$0.18
1.19
-
Price and volume
Market cap
$573M
Beta
1.19
52-week high
$33.33
52-week low
$15.45
Average daily volume
439K
Financial strength
Current ratio
9.374
Quick ratio
8.91
Long term debt to equity
5.291
Total debt to equity
5.87
Interest coverage (TTM)
-23.77%
Profitability
EBITDA (TTM)
28.634
Gross margin (TTM)
81.94%
Net profit margin (TTM)
-1.46%
Operating margin (TTM)
-3.97%
Effective tax rate (TTM)
-128.54%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-1.79%
Return on equity (TTM)
-1.20%
Valuation
Price to revenue (TTM)
1.604
Price to book
1.3
Price to tangible book (TTM)
1.58
Price to free cash flow (TTM)
13.333
Free cash flow yield (TTM)
7.50%
Free cash flow per share (TTM)
148.81%
Growth
Revenue change (TTM)
38.43%
Earnings per share change (TTM)
-83.81%
3-year revenue growth (CAGR)
52.37%
3-year earnings per share growth (CAGR)
-55.14%
What the Analysts think about CSTL
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
Bulls say / Bears say
Castle Biosciences reported a 21% increase in Q1 2025 revenue to $88 million, indicating strong financial performance and growth potential. (tradingview.com)
BTIG raised its price target for Castle Biosciences to $45 from $40, maintaining a Buy rating, reflecting confidence in the company's future prospects. (nasdaq.com)
The company's DecisionDx-Melanoma test surpassed 200,000 orders since launch, demonstrating strong market adoption and potential for continued growth. (tradingview.com)
Castle Biosciences reported a net loss of $25.8 million in Q1 2025, compared to a net loss of $2.5 million in the same period of 2024, indicating increased financial strain. (tradingview.com)
The company discontinued its IDgenetix test offering in May 2025, which may impact future revenue streams and market diversification. (tradingview.com)
Analysts expected a loss of 7 cents per share for Q1 2025, but the company reported an adjusted loss of 20 cents per share, missing expectations and potentially affecting investor confidence. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CSTL Financial Performance
Revenues and expenses
CSTL Earnings Performance
Company profitability
CSTL News
AllArticlesVideos
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
GlobeNewsWire·4 weeks ago
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $573M as of July 11, 2025.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 0 as of July 11, 2025.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.